Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

被引：0

作者：

Singhal, Seema B. ^{[1
]}

Siegel, David Samuel diCapua ^{[2
]}

Martin, Thomas ^{[3
]}

Vij, Ravi ^{[4
]}

Wang, Michael ^{[5
]}

Jakubowiak, Andrzej J. ^{[6
]}

Lonial, Sagar ^{[7
]}

Kukreti, Vishal ^{[8
]}

Zonder, Jeffrey A. ^{[9
]}

Wong, Alvin F. ^{[10
]}

McCulloch, Leanne ^{[10
]}

Kauffman, Michael ^{[10
]}

Badros, Ashraf Z. ^{[11
]}

Niesvizky, Ruben ^{[12
]}

Orlowski, Robert Z. ^{[13
]}

Stewart, A. Keith ^{[14
]}

Jagannath, Sundar ^{[15
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Div Hem Onc, Chicago, IL 60611 USA

[2] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[3] Univ San Francisco, San Francisco, CA 94117 USA

[4] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[5] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[8] Princess Margaret Hosp, Div Hematol Oncol, Toronto, ON M4X 1K9, Canada

[9] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[10] Onyx Pharmaceut, Emeryville, CA USA

[11] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[12] Weill Cornell Med Coll, New York, NY USA

[13] Univ Texas Houston, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[14] Mayo Clin Arizona, Scottsdale, AZ USA

[15] Mt Sinai Med Ctr, Multiple Myeloma Program, New York, NY 10029 USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：814 / 815

页数：2

共 50 条

[31] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Costa, Luciano J.
Davies, Faith E.
Monohan, Gregory P.
Kovacsovics, Tibor
Burwick, Nicholas
Jakubowiak, Andrzej
Kaufman, Jonathan L.
Hong, Wan-Jen
Dail, Monique
Salem, Ahmed Hamed
Yang, Xiaoqing
Masud, Abdullah A.
Munasinghe, Wijith
Ross, Jeremy A.
Bueno, Orlando F.
Kumar, Shaji K.
Stadtmauer, Edward A.
BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
[32] Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM)
Atrash, Shebli
Tullos, Amanda
Panozzo, Susan
Waheed, Sarah
Van Rhee, Frits
Restrepo, Alejandro
Muzaffar, Jameel
Bakhous, Aziz
Grazziutti, Monica
Shahid, Zainab
Apewokin, Senu
Abdallah, Al-Ola A.
Barlogie, Bart
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[33] Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Costa, Luciano J.
Stadtmauer, Edward A.
Morgan, Gareth
Monohan, Gregory
Kovacsovics, Tibor
Burwick, Nicholas
Jakubowiak, Andrzej
Kaufman, Jonathan L.
Mobasher, Mehrdad
Freise, Kevin J.
Ross, Jeremy A.
Pesko, John
Munasinghe, Wijith
Gudipati, Saketh
Mudd, Sarah
Bueno, Orlando
Kumar, Shaji K.
BLOOD, 2018, 132
[34] Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
Chari, Ajai
Larson, Sarah
Holkova, Beata
Cornell, Robert F.
Gasparetto, Cristina
Karanes, Chatchada
Matous, Jeffrey V.
Niesvizky, Ruben
Valent, Jason
Lunning, Matthew
Usmani, Saad Z.
Anderson, Larry D., Jr.
Chang, Lipo
Lee, Yihua
Pak, Yvonne
Salman, Zeena
Graef, Thorsten
Bilotti, Elizabeth
Chhabra, Saurabh
LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2588 - 2594
[35] Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
Nooka, Ajay K.
Badros, Ashraf Z.
Patel, Priti
McCulloch, Leanne
Lonial, Sagar
Kaufman, Jonathan L.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[36] Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM).
Martin, Thomas
Singhal, Seema B.
Vij, Ravi
Wang, Michael
Keith-Stewart, A.
Jagannath, Sundar
Lonial, Sagar
Jakubowiak, Andrzej J.
Kukreti, Vishal
Bahlis, Nizar J.
Alsina, Melissa
Chanan-Khan, Asher A.
Somlo, George
Buadi, Francis
Reu, Frederic J.
Zonder, Jeffrey A.
Song, Kevin
Stadtmauer, Edward A.
Wong, Alvin F.
Vallone, Marcy
Chang, Yu-Lin
Kauffman, Michael
Orlowski, Robert Z.
Siegel, David Samuel diCapua
BLOOD, 2010, 116 (21) : 1249 - 1250
[37] Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
Gasparetto, Cristina
Lipe, Brea
Tuchman, Sascha
Callander, Natalie Scott
Lentzsch, Suzanne
Baljevic, Muhamed
Rossi, Adriana C.
Bahlis, Nizar J.
White, Darell
Chen, Christine
Sutherland, Heather J.
Kotb, Rami
LeBlanc, Richard
Sebag, Michael
Venner, Christopher P.
Bensinger, William
Sheehan, Heidi
Ju, Yawen
Kai, Kazuharu
Schiller, Gary J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[38] A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion
Berdeja, Jesus G.
Gregory, Tara B.
Faber, Edward
Matous, Jeffrey
Hart, Lowell
Mace, Joseph R.
Arrowsmith, Edward R.
Flinn, Ian W.
BLOOD, 2016, 128 (22)
[39] Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency
Badros, Ashraf Z.
Vij, Ravi
Martin, Thomas
Zonder, Jeffrey A.
Woo, Tina
Wang, Zhengping
Lee, Susan
Wong, Alvin
Niesvizky, Ruben
BLOOD, 2009, 114 (22) : 1492 - 1492
[40] A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
Vesole, David H.
Siegel, David Samuel DiCapua
Richter, Joshua Ryan
McNeill, Ann
Anand, Palka
Bednarz, Urszula
Ivanovski, Kristin
McBride, Laura
Raucci, Laura
Batra, Veena
Aleman, Adolfo
Sims, Taliah
Guerrero, Laura
Smith, Judith
Mato, Anthony R.
Bilotti, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →